Mid‐term outcomes of the Pulsta transcatheter pulmonary valve for the native right ventricular outflow tract

• Published in: Catheterization and cardiovascular interventions Vol. 98; no. 5; pp. E724 - E732
• Main Authors: Lee, Sang‐Yun, Kim, Gi Beom, Kim, Seong‐Ho, Jang, So‐Ick, Choi, Jae Young, Kang, I. Seok, Kim, Young‐Hwue
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.11.2021; Wiley Subscription Services, Inc
• Subjects: Adverse events; Catheters; clinical trial; Clinical trials; Heart; Implants; Patients; percutaneous intervention; pulmonary valve disease; Regurgitation; stent design/structure/coatings; Ventricle
• ISSN: 1522-1946; 1522-726X
• DOI: 10.1002/ccd.29865

Objectives The aim of this study is to present the mid‐term outcomes of Pulsta valve. Background The Pulsta valve is a Self‐expandable knitted nitinol‐wire stent mounted with a treated tri‐leaflet α‐Gal‐free porcine pericardial valve for percutaneous pulmonary valve implantation (PPVI) in patients with native right ventricular outflow tract (RVOT) lesions. Methods A multi‐center clinical trial using Pulsta valve® was designed for patients with severe pulmonary regurgitation (PR) in the native RVOT in multiple centers in South Korea and 25 patients were enrolled. Before PPVI, severe PR (mean PR fraction: 45.5 ± 6.9%) and enlarged RV volume (mean indexed RV end‐diastolic volume; 169.7 ± 13.0 ml/m2) was present. The mean age was 21.6 ± 6.6 years old. Results All patients were successfully implanted with 26, 28, or 32 mm diameter of Pulsta valve loaded on the 18 or 20 French delivery catheters. At 6 months follow up, indexed RV end‐diastolic volume was decreased to 126.9 ± 16.9 ml/m2. At mean 33.1 ± 14.3 months follow‐up, the mean value of mean pressure gradient in Pulsta valve was 6.5 ± 3.0 mmhg without significant PR. There was no serious device‐related adverse event. Conclusions A multi‐center clinical trial was completed successfully with planned Pulsta valve implantation and demonstrated good mid‐term effectiveness without device‐related serious adverse events.